自然杀伤细胞展现出它们对抗癌症的价值。 - Suppr

Suppr

超能文献

Natural killer cells show their cancer-fighting worth.

作者信息

Keener Amanda B

出版信息

Nature. 2024 May;629(8014):S4-S6. doi: 10.1038/d41586-024-01427-4.

DOI:10.1038/d41586-024-01427-4

PMID:38811700

Abstract

摘要

相似文献

Natural killer cells show their cancer-fighting worth.

Nature. 2024 May;629(8014):S4-S6. doi: 10.1038/d41586-024-01427-4.

First-in-class cancer therapeutic to stimulate natural killer cells.

Nat Biotechnol. 2006 Jun;24(6):597. doi: 10.1038/nbt0606-597. Epub 2006 Jun 2.

[Cancer immunotherapy].

Duodecim. 1999;115(7):785-94.

Reprogramming of natural killer cells and their use in immunotherapies of solid tumors.

Immunotherapy. 2020 Jun;12(9):605-608. doi: 10.2217/imt-2020-0051. Epub 2020 May 18.

[New era of tumor immunotherapy].

Nihon Rinsho. 2005 Apr;63 Suppl 4:46-55.

Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens.

Nat Rev Drug Discov. 2015 Jul;14(7):487-98. doi: 10.1038/nrd4506. Epub 2015 May 22.

[Unleashing NK cell signaling to improve cancer immunotherapy].

Med Sci (Paris). 2020 Oct;36 Hors série n° 1:50-55. doi: 10.1051/medsci/2020195. Epub 2020 Oct 14.

Innate immune mediators in cancer: between defense and resistance.

Immunol Rev. 2016 Nov;274(1):290-306. doi: 10.1111/imr.12464.

Can the dual-functional capability of CIK cells be used to improve antitumor effects?

Cell Immunol. 2014 Jan;287(1):18-22. doi: 10.1016/j.cellimm.2013.11.009. Epub 2013 Dec 8.

Natural killer cell-based immunotherapeutic strategies.

Cytotherapy. 2005;7(1):16-22. doi: 10.1080/14653240510018000.

引用本文的文献

Adjusting the scope of natural killer cells in cancer therapy.

Cell Mol Immunol. 2025 May 23. doi: 10.1038/s41423-025-01297-4.

Interleukin signaling in the regulation of natural killer cells biology in breast cancer.

Front Immunol. 2024 Sep 24;15:1449441. doi: 10.3389/fimmu.2024.1449441. eCollection 2024.

Feeder cell training shapes the phenotype and function of in vitro expanded natural killer cells.

MedComm (2020). 2024 Sep 23;5(10):e740. doi: 10.1002/mco2.740. eCollection 2024 Oct.

Metabolic reprogramming and immune evasion: the interplay in the tumor microenvironment.

Biomark Res. 2024 Sep 3;12(1):96. doi: 10.1186/s40364-024-00646-1.

本文引用的文献

Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19 B cell tumors: a phase 1/2 trial.

Nat Med. 2024 Mar;30(3):772-784. doi: 10.1038/s41591-023-02785-8. Epub 2024 Jan 18.

Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering.

Sci Adv. 2023 Jul 28;9(30):eadd6997. doi: 10.1126/sciadv.add6997. Epub 2023 Jul 26.

Nicotinamide enhances natural killer cell function and yields remissions in patients with non-Hodgkin lymphoma.

Sci Transl Med. 2023 Jul 19;15(705):eade3341. doi: 10.1126/scitranslmed.ade3341.

Long-term outcomes following CAR T cell therapy: what we know so far.

Nat Rev Clin Oncol. 2023 Jun;20(6):359-371. doi: 10.1038/s41571-023-00754-1. Epub 2023 Apr 13.

Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant.

Cell Rep Med. 2022 Oct 18;3(10):100783. doi: 10.1016/j.xcrm.2022.100783.

Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia.

Sci Transl Med. 2022 Feb 23;14(633):eabm1375. doi: 10.1126/scitranslmed.abm1375.

Toxicities of CD19 CAR-T cell immunotherapy.

Am J Hematol. 2019 May;94(S1):S42-S49. doi: 10.1002/ajh.25445. Epub 2019 Mar 6.

Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia.

Sci Transl Med. 2016 Sep 21;8(357):357ra123. doi: 10.1126/scitranslmed.aaf2341.

Cytokine-induced memory-like natural killer cells.

Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):1915-9. doi: 10.1073/pnas.0813192106. Epub 2009 Jan 30.

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.

Blood. 2005 Apr 15;105(8):3051-7. doi: 10.1182/blood-2004-07-2974. Epub 2005 Jan 4.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Natural killer cells show their cancer-fighting worth.

Nature. 2024 May;629(8014):S4-S6. doi: 10.1038/d41586-024-01427-4.

First-in-class cancer therapeutic to stimulate natural killer cells.

Nat Biotechnol. 2006 Jun;24(6):597. doi: 10.1038/nbt0606-597. Epub 2006 Jun 2.

[Cancer immunotherapy].

Duodecim. 1999;115(7):785-94.

Reprogramming of natural killer cells and their use in immunotherapies of solid tumors.

Immunotherapy. 2020 Jun;12(9):605-608. doi: 10.2217/imt-2020-0051. Epub 2020 May 18.

[New era of tumor immunotherapy].

Nihon Rinsho. 2005 Apr;63 Suppl 4:46-55.

Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens.

Nat Rev Drug Discov. 2015 Jul;14(7):487-98. doi: 10.1038/nrd4506. Epub 2015 May 22.

[Unleashing NK cell signaling to improve cancer immunotherapy].

Med Sci (Paris). 2020 Oct;36 Hors série n° 1:50-55. doi: 10.1051/medsci/2020195. Epub 2020 Oct 14.

Innate immune mediators in cancer: between defense and resistance.

Immunol Rev. 2016 Nov;274(1):290-306. doi: 10.1111/imr.12464.

Can the dual-functional capability of CIK cells be used to improve antitumor effects?

Cell Immunol. 2014 Jan;287(1):18-22. doi: 10.1016/j.cellimm.2013.11.009. Epub 2013 Dec 8.

Natural killer cell-based immunotherapeutic strategies.

Cytotherapy. 2005;7(1):16-22. doi: 10.1080/14653240510018000.

引用本文的文献

Adjusting the scope of natural killer cells in cancer therapy.

Cell Mol Immunol. 2025 May 23. doi: 10.1038/s41423-025-01297-4.

Interleukin signaling in the regulation of natural killer cells biology in breast cancer.

Front Immunol. 2024 Sep 24;15:1449441. doi: 10.3389/fimmu.2024.1449441. eCollection 2024.

Feeder cell training shapes the phenotype and function of in vitro expanded natural killer cells.

MedComm (2020). 2024 Sep 23;5(10):e740. doi: 10.1002/mco2.740. eCollection 2024 Oct.

Metabolic reprogramming and immune evasion: the interplay in the tumor microenvironment.

Biomark Res. 2024 Sep 3;12(1):96. doi: 10.1186/s40364-024-00646-1.

本文引用的文献

Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19 B cell tumors: a phase 1/2 trial.

Nat Med. 2024 Mar;30(3):772-784. doi: 10.1038/s41591-023-02785-8. Epub 2024 Jan 18.

Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering.

Sci Adv. 2023 Jul 28;9(30):eadd6997. doi: 10.1126/sciadv.add6997. Epub 2023 Jul 26.

Nicotinamide enhances natural killer cell function and yields remissions in patients with non-Hodgkin lymphoma.

Sci Transl Med. 2023 Jul 19;15(705):eade3341. doi: 10.1126/scitranslmed.ade3341.

Long-term outcomes following CAR T cell therapy: what we know so far.

Nat Rev Clin Oncol. 2023 Jun;20(6):359-371. doi: 10.1038/s41571-023-00754-1. Epub 2023 Apr 13.

Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant.

Cell Rep Med. 2022 Oct 18;3(10):100783. doi: 10.1016/j.xcrm.2022.100783.

Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia.

Sci Transl Med. 2022 Feb 23;14(633):eabm1375. doi: 10.1126/scitranslmed.abm1375.

Toxicities of CD19 CAR-T cell immunotherapy.

Am J Hematol. 2019 May;94(S1):S42-S49. doi: 10.1002/ajh.25445. Epub 2019 Mar 6.

Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia.

Sci Transl Med. 2016 Sep 21;8(357):357ra123. doi: 10.1126/scitranslmed.aaf2341.

Cytokine-induced memory-like natural killer cells.

Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):1915-9. doi: 10.1073/pnas.0813192106. Epub 2009 Jan 30.

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.

Blood. 2005 Apr 15;105(8):3051-7. doi: 10.1182/blood-2004-07-2974. Epub 2005 Jan 4.